Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model.
Hepatocellular carcinoma (HCC) is the 2nd leading cause of cancer-related deaths every year globally.The most common form of treatment, hepatic arterial infusion (HAI), involves the direct injection of doxorubicin (DOX) into the hepatic artery.It is plagued with limited therapeutic efficacy and the occurrence of severe toxicities (e.g.cardiotoxicit